

Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	5 February 2024
TO:	North, Edmonton, and Central Zones (sites that refer testing to Edmonton): All Physicians, Nurses, and Managers
FROM:	Clinical Biochemistry, Alberta Precision Labs (APL)
RE:	Implementation of Extractable Nuclear Antigen Antibodies Test on the Bioplex Instrument

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

• Effective <u>February 5, 2024</u>, serum *Extractable Nuclear Antigen Antibodies (ENA)* testing at the University of Alberta Hospital, Special Chemistry laboratory in Edmonton, will transition from the Luminex analyzer to the Bioplex analyzer to align with the Calgary Immunochemistry laboratory.

Background

- On December 11, 2023, Alberta Precision Laboratories began Bioplex implementation as part of a large-scale provincial project to standardize chemistry instrumentation. This initiative will reduce the variation of autoantibody immunoassays in Alberta.
- ENA antibodies are useful for evaluating patients suspected of having connective tissue disease following a positive Anti-Nuclear Antibody (ANA) screen.

How this will impact you

- The components of the ENA panel will change.
 - ✓ Anti-chromatin will replace Anti-histone for investigation of drug-induced lupus.
 - ✓ New autoantibodies detected include ribosomal P, SS-A/Ro 52, RNP A, RNP 68, and SmRNP.
- ENA units will change from mean florescence units (MFU) to autoantibody index (AI).
- The new lower limit for the *ENA* test is <0.2 and the new upper limit is >8.
- The reference interval will change from <120 MFU to ≤ 0.9 Al.
- Known patients monitored overtime will require re-baselining due to differences in *ENA* results and reference intervals between Luminex and Bioplex *ENA* methods.

Action Required

- Be aware of changes to ENA assay and lab reporting. Refer to APL ENA test directory.
- Patients having serial monitoring at the time of transition may need a new baseline for comparison.
- For urgent requests, contact the on-call clinical biochemist.

Questions/Concerns

• Dr. Kareena Schnabl, Clinical Biochemist: 780 407-3186; kareena.schnabl@albertaprecisionlabs.ca

Approved by

- Dr. Michael Mengel, Medical Director, North Sector, APL
- Dr. Allison Venner, Associate Section Chief, Clinical Biochemistry, APL
- Dr. Paul Klonowski, Associate Medical Director, South Sector, APL

Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.